Navigation Links
Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
Date:10/1/2009

PALO ALTO, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer (NSCLC) in a leading peer reviewed publication, the Journal of Thoracic Oncology, October 2009; Vol. 4, No. 10. Data on this study were presented at the 98th annual meeting of the American Association for Cancer Research (AACR) on April 17, 2007.

One hundred twenty-nine patients were treated with TELCYTA in combination with carboplatin and paclitaxel, of whom 100 were continuing to respond at the end of combination therapy and eligible to receive single agent TELCYTA maintenance therapy. Those patients who received the TELCYTA combination therapy followed by TELCYTA maintenance therapy vs. no maintenance therapy had a median progression-free survival (PFS) of 6.8 months vs. 3.9 months, respectively (p< 0.0001). The difference in PFS correlated with a median survival of 16.8 months in the maintenance group vs. 8.8 months for those without maintenance therapy (p<0.0001). TELCYTA in combination with carboplatin and paclitaxel chemotherapy followed by TELCYTA maintenance therapy was well tolerated. TELCYTA may be suited to application as maintenance therapy, an area of current intense interest for the treatment of lung cancer patients. In addition, the regimen appeared active across all types of NSCLC and ongoing investigations are attempting to identify the characteristics of the NSCLC population most likely to benefit from this approach.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to trea
'/>"/>

SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
6. Telik Announces Presentation at ASCO Annual Meeting
7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 China Nepstar Chain Drugstore ... a leading retail drugstore chain in China based ... announced its unaudited financial results for the fourth ... Financial HighlightsFor the quarter ended December 31, 2014: ... compared to the fourth quarter of 2013 ...
(Date:3/27/2015)... 2015 Across the global healthcare landscape, the ... clinical development, market education, and regulatory compliance. As emerging ... function is expected to increase in prominence and follow ... According to research by benchmarking firm, Best Practices, LLC, ... to Medical Affairs. Among companies in India ...
(Date:3/27/2015)... Levi & Korsinsky announces it has commenced ... ) concerning possible violations of federal securities laws. The ... connection with its study of the drug OHR-102. To ... contact Joseph E. Levi, Esq. either via ... (212) 363-7500, toll-free: (877) 363-5972. Levi & ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 11China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 12China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 13China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 14China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results 15Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
... SANTA BARBARA, Calif., June 20, 2011 Inogen has ... (MDEA) for the Inogen One Portable Oxygen Concentrator.  The ... program that exclusively recognizes contributions and advances in the ... One, developed by Goleta, California based Inogen, Inc. is ...
... 2011 The U.S. Food and Drug Administration today ... and approval of an artificial pancreas system to treat ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Type ... pancreas produces little or no insulin, a hormone needed ...
Cached Medicine Technology:Inogen One Wins Gold Medical Design Excellence Award 2FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 2FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 3
(Date:3/30/2015)... This report studies the global ... forecast period of 2014 to 2019. This market ... 6.5% from 2014 to 2019. , Further Inquiry ... the global pharmacovigilance and drug safety software market ... basis of functionality, namely, adverse event reporting software, ...
(Date:3/30/2015)... Dr. Shahdad Arami is ... will receive $200 off their Invisalign treatment. Many people ... wearing a mouthful of metal. Invisalign offers an alternative. ... braces is effective for straightening teeth but has no ... their oral appearance. The Invisalign system allows both teenagers ...
(Date:3/30/2015)... Angeles, CA (PRWEB) March 30, 2015 ... traditional blue polo for yellow to inspire courage in ... suffers from Severe Combined Immunodeficiency (SCID). SCID causes affected ... bone marrow transplant is needed to allow the development ... second transplant last Friday, created a video with his ...
(Date:3/30/2015)... V/NO (Virtually No Alcohol) Wines have a ... opening/closing and for reuse. Consumers simply twist the cup, turn ... Yorkers, professionals, and basically anyone can now enjoy a ... back socially or pair with meals at work, home, or ... wine and that means Napa Wine grapes undergo the ...
(Date:3/30/2015)... TX (PRWEB) March 30, 2015 ... been Drummond Certified™ in the second AS4 test ... Inc., the trusted leader in interoperability software testing. ... Oracle and Software AG participated in this vendor-neutral ... represents the first AS4 interoperability certifications for IBM, ...
Breaking Medicine News(10 mins):Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:Northridge Cosmetic Dentist, Dr. Arami, is Now Offering a New Promotion on Invisalign 2Health News:24Hr HomeCare Staff Hosts #WearYellowForSeth Campaign for Five-Year-Old Boy with Severe Combined Immunodeficiency 2Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 3
... Reporter , THURSDAY, June 2 (HealthDay News) -- New ... part of the plan, don,t appear to harm the ... clear low-carb is effective for weight loss," said study ... exercise physiology at the Johns Hopkins University School of ...
... liver diseases such as hepatitis C (HCV) are typically ... disease progression. For patients who question whether less invasive ... consider. Elastography and serum markers are two such diagnostic ... issue of Hepatology , a journal of the ...
... HealthDay Reporter , THURSDAY, June 2 (HealthDay ... more likely to suffer from anxiety, loneliness, low self-esteem ... and math test scores, new research suggests. Children ... during the potentially disruptive period before their parents divorce, ...
... study from North Carolina State University shows that talking about ... transgender community. The finding may help efforts to promote safer ... and also sheds light on broader questions related to safer ... is the fact that we,re seeing evidence of devastatingly high ...
... 2, 2011 In a multicenter clinical trial, ... higher doses of stereotactic radiation therapy requiring fewer ... low-to-intermediate-risk prostate cancer. Results of the trial, ... , showed that stereotactic body radiation therapy (SBRT), ...
... of the most lethal cancers, advanced melanoma, has improved response ... immunotherapy drug Interleukin-2, according to research led by scientists from ... University Health Goshen Center for Cancer Care. The ... of Medicine , mark the first vaccine study in the ...
Cached Medicine News:Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 2Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 3Health News:Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis 2Health News:Divorce Can Hurt Kids' Math Scores, Friendships 2Health News:Divorce Can Hurt Kids' Math Scores, Friendships 3Health News:Safer sex: Study examines sexual communication in transgender community 2Health News:Higher doses of radiation in fewer treatments proved safe, effective for low-risk prostate cancer 2Health News:Therapeutic melanoma vaccine improves response rate, progression-free survival 2Health News:Therapeutic melanoma vaccine improves response rate, progression-free survival 3
... HmX offers three-dimensional VCS ... specificity and efficiency in ... reticulocyte analysis. With its ... dependability, HmX is an ...
... utilize the infinity-corrected optical system ... in cell checking. The CKX31 ... suited to routine applications in ... culture and embryology to immunology ...
The BX41 offers an outstanding range of features and optical performance for the clinical market. With an emphasis on high-quality optics and a rigid frame, the BX41 offers improved versatility and e...
Advanced ergonomic design allows greater comfort even after long hours of use. The focus knob and stage handle are located equidistant from the operator, permitting one-handed operation in a natural ...
Medicine Products: